Literature DB >> 945494

The pharmacokinetics of pyridostigmine.

S L Cohan, J L Pohlmann, J Mikszewski, D S O'Doherty.   

Abstract

A simplified gas chromatographic method for measuring quaternary ammonium compounds has been developed and used to measure the serum concentration of pyridostigmine in human beings. Pyridostigmine is present in the serum within 1 hour after oral administration and reaches a peak at 2 hours. Results in several patients suggest that the serum concentration achieved is related to the size of the dose and that there is a relationship between serum concentration and clinical response.

Entities:  

Mesh：

Substances：

Year:  1976        PMID： 945494     DOI： 10.1212/wnl.26.6.536

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


  11 in total

1.  Pharmacodynamic analysis of contractile potentiation by cholinesterase inhibitors in rats.

Authors:  K Yamamoto; Y Sawada; T Iga
Journal:  J Pharmacokinet Biopharm       Date:  1996-08

2.  A pharmacokinetic study of neostigmine in man using gas chromatography-mass spectrometry.

Authors:  S M Aquilonius; S A Eckernäs; P Hartvig; J Hultman; B Lindström; P O Osterman
Journal:  Eur J Clin Pharmacol       Date:  1979-06-12       Impact factor: 2.953

Review 3.  Clinical pharmacokinetics of cholinesterase inhibitors.

Authors:  S M Aquilonius; P Hartvig
Journal:  Clin Pharmacokinet       Date:  1986 May-Jun       Impact factor: 6.447

Review 4.  Pharmacokinetics in intravenous anaesthetic practice.

Authors:  P Duvaldestin
Journal:  Clin Pharmacokinet       Date:  1981 Jan-Feb       Impact factor: 6.447

5.  Clinical pharmacology of pyridostigmine and neostigmine in patients with myasthenia gravis.

Authors:  S M Aquilonius; S A Eckernäs; P Hartvig; B Lindström; P O Osterman; E Stålberg
Journal:  J Neurol Neurosurg Psychiatry       Date:  1983-10       Impact factor: 10.154

6.  Anaesthesia for transcervical thymectomy in myasthenia gravis.

Authors:  J B Eisencraft
Journal:  Ann R Coll Surg Engl       Date:  1985-11       Impact factor: 1.891

7.  The relationship of plasma levels of pyridostigmine to clinical effect in patients with myasthenia gravis.

Authors:  S C Davison; N M Hyman; A Dehghan; K Chan
Journal:  J Neurol Neurosurg Psychiatry       Date:  1981-12       Impact factor: 10.154

8.  Proceeding of the British Pharmacological Society, Clinical Pharmacology Section, 16-18th December, 1980, University of London. Abstracts.

Authors: 
Journal:  Br J Clin Pharmacol       Date:  1981-04       Impact factor: 4.335

9.  Controversies about the treatment of myasthenia gravis.

Authors:  L P Rowland
Journal:  J Neurol Neurosurg Psychiatry       Date:  1980-07       Impact factor: 10.154

10.  Pharmacokinetics and oral bioavailability of pyridostigmine in man.

Authors:  S M Aquilonius; S A Eckernäs; P Hartvig; B Lindström; P O Osterman
Journal:  Eur J Clin Pharmacol       Date:  1980-11       Impact factor: 2.953
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.